GFAP and Alzheimer disease: Future studies should aim to replicate our findings along the AD pathology continuum, tau pathology, neurofilament light (NfL), as well as use other plasma biomarkers (e.g., glial fibrillar acidic protein [GFAP]), as they may provider greater insight into the progression of cerebral amyloid and tau pathology and cognitive decline in SSA populations.